PMC6637272_01
The therapy of the first patient, CsA: cyclosporine A, IVIG: intravenous immunoglobulin, IVCY: intravenous pulse cyclophosphamide, Steroids: methylprednisolone, SMZco: Trimethoprim/sulfamethoxazole; P/F: PO2/FIO2.
gr1.jpg
PMC6637272_01_gr1.jpg
fig1
Once administered to our hospital, the patient was immediately treated with 8mg/d methylprednisolone combined with 400mg/kg. d immunoglobulin for 3 days, following methylprednisolone 40 mg for 5 days and the condition continued to deteriorate (Fig. 1).
Changes in HRCT findings of Case 1. A, Before DNA immunoadsorption, reticulation and consolidation could be seen. B: two months later after DNA immunoadsorption, faded reticulation while increased pleural effusion in the left lung could be found; C: two years later after DNA immunoadsorption, reticulation and consolidation evaporated virtually and gradually reduced pleural effusion in the left lung could be found.
gr2.jpg
PMC6637272_01_gr2.jpg
fig2
Three months and two years later re-examine HRCT showed patently reduced reticulations. (Fig. 2).
PMC6637272_02
The therapy of the second patient, CsA: cyclosporine A, IVIG: intravenous immunoglobulin, IVCY: intravenous pulse cyclophosphamide, Steroids: methylprednisolone, SMZco: Trimethoprim/sulfamethoxazole; P/F: PO2/FIO2.
gr3.jpg
PMC6637272_02_gr3.jpg
fig3
Once admitted to our hospital, he was administrated with 1g methylprednisolone pulse therapy per day for 3 days and 400mg cyclophosphamide (Fig. 3) for rapid progression observed on HRCT.